tbuckley/cabot-search huggingface dataset:
Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma
Authors: Dong Ho Lee, Jeong Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Jeong-Hoon Lee, Su Jong Yu, Joon Koo Han
Journal: Liver Cancer (2018)

To evaluate the prognostic value of liver stiffness (LS) measured using two-dimensional (2D) shear-wave elastography (SWE) in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation (RFA).The Institutional Review Board approved this retrospective study and informed consent was obtained from all patients. A total of 134 patients with up to 3 HCCs ≤5 cm who had undergone pre-procedural 2D-SWE prior to RFA treatment between January 2012 and December 2013 were enrolled. LS values were measured using real-time 2D-SWE before RFA on the procedural day. After a mean follow-up of 33.8 ± 9.9 months, we analyzed the overall survival after RFA using the Kaplan-Meier method and Cox proportional hazard regression model. The optimal cutoff LS value to predict overall survival was determined using the minimal p value approach.During the follow-up period, 22 patients died, and the estimated 1- and 3-year overall survival rates were 96.4 and 85.8%, respectively. LS measured by 2D-SWE was found to be a significant predictive factor for overall survival after RFA of HCCs, as was the presence of extrahepatic metastases. As for the optimal cutoff LS value for the prediction of overall survival, it was determined to be 13.3 kPa. In our study, 71 patients had LS values ≥13.3 kPa, and the estimated 3-year overall survival was 76.8% compared to 96.3% in 63 patients with LS values <13.3 kPa. This difference was statistically significant (hazard ratio = 4.30 [1.26-14.7]; p = 0.020).LS values measured by 2D-SWE was a significant predictive factor for overall survival after RFA for HCC.
Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study
Authors: Anne Gedebjerg, Szimonetta Komjáthiné Szépligeti, Laura-Maria Holm Wackerhausen, Erzsébet Horváth-Puhó, Ronald Dahl, Jens Georg Hansen, Henrik Toft Sørensen, Mette Nørgaard, Peter Lange, Reimar Wernich Thomsen
Journal: The Lancet Respiratory Medicine (2018)
Autoimmune hemolytic anemia and hemolytic transfusion reactions in two patients with Waldenstrom macroglobulinemia treated with combination BTK inhibitor and PD-1 inhibitor
Authors: Jad Othman, Emma Verner, Constantine S. Tam, Jane Huang, Leo Lin, James Hilger, Judith Trotman, Robin E. Gasiorowski
Journal: Blood (2017)
A Simple Method of Blood Collection to Detect Mutational Changes [BTK Gene Analysis] in Vietnamese Children With XLA [X-Linked Agammaglobulinemia]
Authors: Anh V.T. Nguyen, Le Thi Minh Huong, Gesmar Segundo, Roger Kobayashi, Nguyen Thi Van Anh, Nguyen Ngoc Quynh Le, Thuc Thanh Huyen, Le Thanh Hai, Troy R. Torgerson, Hans D. Ochs
Journal: Journal of Allergy and Clinical Immunology (2018)
Lithium and Dementia
Authors: Perminder Sachdev
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Completely Non-Myeloablative/Non-Lymphoablative Conditioning for BMT/HSCT Using Anti-Ckit Immunotoxins
Authors: Agnieszka Czechowicz, Rahul Palchaudhuri, Amelia Scheck, Jonathan Hoggatt, Borja Saez, David T. Scadden, Derrick J. Rossi
Journal: Blood (2016)
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
Authors: Sanjay Kaul
Journal: Diabetes Care (2018)

In the article cited above, there are typographical errors in Table 3 with regard to the values for hospitalization for heart …
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years
Authors: Julie Lemieux, Michael D. Brundage, Wendy R. Parulekar, Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, Paul Celano, Hyman Muss, Julie Gralow, Kathrin Strasser-Weippl, Kate Whelan, Dongsheng Tu, Timothy J. Whelan
Journal: Journal of Clinical Oncology (2018)

Purpose MA.17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and menopause-specific QOL (MENQOL; four symptom domains) at baseline and every 12 months up to 60 months. QOL assessment was mandatory for Canadian Cancer Trials Group centers but optional for centers in other groups. Mean change scores from baseline were calculated. Results One thousand nine hundred eighteen women were randomly assigned, and 1,428 women completed the baseline QOL assessment. Compliance with QOL measures was > 85%. Baseline summary scores for the SF-36 physical component summary (47.5 for letrozole and 47.9 for placebo) and mental component summary (55.5 for letrozole and 54.8 for placebo) were close to the population norms of 50. No differences were seen between groups in mean change scores for the SF-36 physical and mental component summaries and the other eight QOL domains except for the role-physical subscale. No difference was found in any of the four domains of the MENQOL Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL.
Flavonoids, Dairy Foods, and Cardiovascular and Metabolic Health
Authors: Dariush Mozaffarian, Jason H.Y. Wu
Journal: Circulation Research (2018)

A growing body of nutritional science highlights the complex mechanisms and pleiotropic pathways of cardiometabolic effects of different foods. Among these, some of the most exciting advances are occurring in the area of flavonoids, bioactive phytochemicals found in plant foods; and in the area of dairy, including milk, yogurt, and cheese. Many of the relevant ingredients and mechanistic pathways are now being clarified, shedding new light on both the ingredients and the pathways for how diet influences health and well-being. Flavonoids, for example, have effects on skeletal muscle, adipocytes, liver, and pancreas, and myocardial, renal, and immune cells, for instance, related to 5′-monophosphate-activated protein kinase phosphorylation, endothelial NO synthase activation, and suppression of NF-κB (nuclear factor-κB) and TLR4 (toll-like receptor 4). Effects of dairy are similarly complex and may be mediated by specific amino acids, medium-chain and odd-chain saturated fats, unsaturated fats, branched-chain fats, natural trans fats, probiotics, vitamin K1/K2, and calcium, as well as by processing such as fermentation and homogenization. These characteristics of dairy foods influence diverse pathways including related to mammalian target of rapamycin, silent information regulator transcript-1, angiotensin-converting enzyme, peroxisome proliferator–activated receptors, osteocalcin, matrix glutamate protein, hepatic de novo lipogenesis, hepatic and adipose fatty acid oxidation and inflammation, and gut microbiome interactions such as intestinal integrity and endotoxemia. The complexity of these emerging pathways and corresponding biological responses highlights the rapid advances in nutritional science and the continued need to generate robust empirical evidence on the mechanistic and clinical effects of specific foods.
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease
Authors: Manesh R. Patel, John H. Calhoon, Gregory J. Dehmer, James Aaron Grantham, Thomas M. Maddox, David J. Maron, Peter K. Smith
Journal: Journal of the American College of Cardiology (2017)
Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018
Authors: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, Philip Cornford, Alex Govorov, Ann M. Henry, Thomas B. Lam, Malcolm D. Mason, Olivier Rouvière, Maria De Santis, Peter-Paul M. Willemse, Hendrik van Poppel, Nicolas Mottet
Journal: European Urology (2018)
Remission or low disease activity as a target in systemic lupus erythematosus
Authors: Manuel Francisco Ugarte-Gil, Daniel Wojdyla, Guillermo J Pons-Estel, Bernardo A Pons-Estel, Graciela S Alarcón
Journal: Annals of the Rheumatic Diseases (2018)

We read the report by Zen et al 1 on the impact of lupus low disease activity state (LLDAS) on damage accrual with great interest and would like to congratulate the authors on their work. In this single-centre Caucasian cohort, followed for 7 years, only 38 of their 293 patients (11.3%) failed to achieve LLDAS for at least 1 year; moreover, of the 255 patients who achieved LLDAS for at least 1 year, 246 (96.5%) also satisfied the definition of remission for the same length of time. And, in 214 (83.9%) patients, the duration of remission was the same as that of LLDAS. Being in LLDAS for at least 2 years was associated with a reduced risk of damage; …
Midazolam is a major cause of intraoperative immediate hypersensitivity reactions
Authors: Ana Carolina D'Onofrio E Silva, Cristiane Fernandes Boralli, Nathalia Coelho Portilho, Laila Sabino Garro, Marisa Rosimeire Ribeiro, Manoela Crespo De Magalhaes, Lucila Campos, Antonio Abilio Motta, Jorge Elias Kalil Filho, Pedro Giavina-Bianchi, Marcelo V. Aun
Journal: Journal of Allergy and Clinical Immunology (2018)
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia
Authors: Dirk Bassler, Eric S. Shinwell, Mikko Hallman, Pierre-Henri Jarreau, Richard Plavka, Virgilio Carnielli, Christoph Meisner, Corinna Engel, Alexander Koch, Karen Kreutzer, Johannes N. van den Anker, Matthias Schwab, Henry L. Halliday, Christian F. Poets
Journal: New England Journal of Medicine (2018)

The long-term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain.
Response to: ‘Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis’ by Chevreau <i>et al</i>
Authors: Maria Karolina Jonsson, Nina Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Désirée van der Heijde, Tore Kristian Kvien, Bjørg-Tilde Svanes Fevang, Siri Lillegraven, Espen Andre Haavardsholm
Journal: Annals of the Rheumatic Diseases (2018)

We appreciate the additional data regarding calprotectin and radiographic progression provided by Chevreau et al 1 as an eLetter addressing our published research paper.2 It is important to explore new biomarkers in different cohorts of patients with early and established rheumatoid arthritis (RA). Calprotectin levels have previously been shown to be associated with joint damage in established RA.3 4 Hammer et al 5 have shown that calprotectin was an independent predictor of radiographic joint damage after 10 years of follow-up. Chevreau et al present data on baseline calprotectin as a predictor of rapid radiographic progression (defined as an increase of ≥5 van der Heijde Sharp score units/year) in a large cohort of patients with early RA, and did not find calprotectin to be associated with structural damage when baseline erosions were …
Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial
Authors: Jianfeng Yang, Jing Wang, Haibin Zhou, Yifeng Zhou, Yang Wang, Hangbin Jin, Qifeng Lou, Xiaofeng Zhang
Journal: Endoscopy (2018)

Abstract Background Endoscopic placement of biliary stents to relieve jaundice is the main palliative treatment for unresectable extrahepatic cholangiocarcinoma. Endoscopic biliary radiofrequency ablation (RFA) has been reported to prolong stent patency, which may be beneficial in improving patient survival. However, available evidence is still insufficient, as most reported studies are retrospective case series. The aim of this study was to explore the clinical effect and safety of RFA in patients with unresectable extrahepatic cholangiocarcinoma. Methods 65 patients with unresectable extrahepatic cholangiocarcinoma, except Bismuth type III and IV hilar cholangiocarcinoma, were enrolled and randomly underwent either RFA combined with biliary stenting (RFA + stent group; n = 32) or biliary stent only (stent-only group; n = 33). Overall survival time, stent patency period, and postoperative adverse events were recorded. Results In the 21-month follow-up period, the overall mean survival time was significantly longer in the RFA + stent group than in the stent-only group (13.2 ± 0.6 vs. 8.3 ± 0.5 months; P &lt; 0.001). The mean stent patency period of the RFA + stent group was also significantly longer than that of the stent-only group (6.8 vs. 3.4 months; P = 0.02). There was no significant difference in the incidence of postoperative adverse events between the two groups (6.3 % [2/32] vs. 9.1 % [3/33]; P = 0.67). Conclusion Endoscopic RFA combined with stenting can significantly prolong survival and the stent patency period without increasing the incidence of adverse events in patients with extrahepatic cholangiocarcinoma patient, except Bismuth type III and IV hilar cholangiocarcinoma. This approach can be considered as a safe and effective palliative treatment for these patients.
Nanomedicine: Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines (Adv. Healthcare Mater. 1/2018)
Authors: Vimalkumar Balasubramanian, Zehua Liu, Jouni Hirvonen, Hélder A. Santos
Journal: Advanced Healthcare Materials (2018)

Nanomedicine is emerging as effective therapeutic strategy for cancer therapy. In addition, cancer nanomedicine is at the interface of several diverse fields and this, taken together with the complexities of nanomedicine and cancer, requires a multidisciplinary effort to advance the understanding and development of cancer-specific nanomedicine in order to meet the current challenges in translating nanomedicine into the clinic. In article number 1700432 Vimalkumar Balasubramanian, Hélder A. Santos, and co-workers review nanomedicine for cancer therapy.
Guideline: Experts recommend a single dose of oral steroids for pain relief in acute sore throat
Authors: Alexander W. Chessman
Journal: Annals of Internal Medicine (2018)

ACP Journal Club16 January 2018Guideline: Experts recommend a single dose of oral steroids for pain relief in acute sore throatAlexander W. Chessman, MDAlexander W. Chessman, MDMedical University of South Carolina, Charleston, South Carolina, USA (A.W.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-168-2-002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationAertgeerts B, Agoritsas T, Siemieniuk RA, et al. Corticosteroids for sore throat: a clinical practice guideline. BMJ. 2017;358:j4090. https://pubmed.ncbi.nlm.nih.gov/28931507Clinical Impact RatingsGIM/FP/GP: Emergency Med: References1 Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:519-28. [PMID: 26258555] Google Scholar2 Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013;11:CD000023. [PMID: 24190439] Google Scholar3 Gehanno P, Dreiser RL, Ionescu E, Gold M, Liu JM. Lowest effective single dose of diclofenac for antipyretic and analgesic effects in acute febrile sore throat. Clin Drug Investig. 2003;23:263-71. [PMID: 17535039] Google Scholar4 Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44:489-506. [PMID: 20150507] Google Scholar5 Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. [PMID: 28404617] Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical University of South Carolina, Charleston, South Carolina, USA (A.W.C.)This article was published at Annals.org on 2 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 January 2018Volume 168, Issue 2Page: JC2KeywordsAntibioticsChildrenGrading of Recommendations Assessment Development and EvaluationNSAIDsPharyngitisSurgerySystematic reviewsTreatment guidelinesVenous thromboembolismVisual analog scale ePublished: 16 January 2018 Issue Published: 16 January 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Trends in Carotid Revascularization Procedures
Authors: Mohamad A. Hussain, Deepak L. Bhatt, Mohammed Al-Omran
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16764: Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus and Heart Failure or Kidney Dysfunction - Observations From the SAVOR-TIMI 53 Trial
Authors: Brian A Bergmark, Deepak L Bhatt, Darren McGuire, Avivit Cahn, Ofri Mosenzon, Philippe G Steg, KyungAh Im, Estella Kanevsky, Itamar Raz, Eugene Braunwald, Benjamin M Scirica
Journal: Circulation (2016)

Introduction: Metformin is the recommended first line therapy for T2DM. The safety of metformin in patients with heart failure (HF) or chronic kidney disease (CKD) remains uncertain. Hypothesis: Me...
Abstract A19: Pulmonary microthrombosis enhances tumorigenesis via myeloid hypoxia-inducible factors
Authors: Colin E. Evans, Asis Palazon, Jingwei Sim, Petros A. Tyrakis, Par-Ola Bendahl, Mattias Belting, Helene Rundqvist, Cristina Branco, Randall S. Johnson
Journal: Cancer Research (2016)

Abstract Thrombosis causes local blood flow restriction and tissue hypoxia, and both of these are associated with tumor cell metastasis. To better understand the regulation of thrombosis-induced metastasis, we created a model incorporating elements of both processes. Controlled induction of pulmonary microthrombosis caused an increase in expression of first hypoxia-inducible factor (HIF)1α, and subsequently HIF2α. Induction of thrombosis before the introduction of tumor cells to venous circulation had no effect on pulmonary tumor number or size; but thrombosis at the time of tumor cell seeding increased number and size of tumors in the lung. Thrombosis on the day after seeding of tumor cells caused an even greater increase in tumor number and size, and this effect persisted until even when thrombosis was induced five days after the introduction of tumor cells into the blood. Experiments on myeloid HIF1α or HIF2α knockout mice demonstrated that loss of either HIF1α or HIF2α eliminated the advantage given to pulmonary tumorigenesis by thrombotic insult. In primary human tumours, markers of thrombosis were positively correlated with expression of the 2 HIFα isoforms. These data demonstrate the importance of microthrombosis in a novel model of metastasis and the essential role of the myeloid cell-specific HIFα response in mediating this process. Citation Format: Colin E. Evans, Asis Palazon, Jingwei Sim, Petros A. Tyrakis, Par-Ola Bendahl, Mattias Belting, Helene Rundqvist, Cristina Branco, Randall S. Johnson. Pulmonary microthrombosis enhances tumorigenesis via myeloid hypoxia-inducible factors. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A19.
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity
Authors: Paulina Salminen, Mika Helmiö, Jari Ovaska, Anne Juuti, Marja Leivonen, Pipsa Peromaa-Haavisto, Saija Hurme, Minna Soinio, Pirjo Nuutila, Mikael Victorzon
Journal: JAMA (2018)

Laparoscopic sleeve gastrectomy for treatment of morbid obesity has increased substantially despite the lack of long-term results compared with laparoscopic Roux-en-Y gastric bypass.
Rethinking neoadjuvant chemotherapy for breast cancer
Authors: Jayant S Vaidya, Samuele Massarut, Hrisheekesh J Vaidya, Emma C Alexander, Thomas Richards, Jochem A Caris, Bhawna Sirohi, Jeffrey S Tobias
Journal: BMJ (2018)

As evidence questioning the rationale behind neoadjuvant chemotherapy in breast cancer grows, Jayant Vaidya and colleagues say we must reconsider the current treatment options